In trial, prioritised, and non-prioritsed interventions

In trial

Simvaststain

First reviewed: April 2023     In trial: tbc

Simvastatin competitively inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, an enzyme involved in cholesterol synthesis.

Baricitinib

First reviewed: April 2023     In trial: tbc

Baricitinib selectively and reversibly inhibits the Janus-associated tyrosine kinases JAK1 and JAK2.

Prioritised

Atibuclimab

First reviewed: April 2023     Priority: 1

Atibuclimab (IC14) is a chimeric CD14 antibody

Complement inhibitors

First reviewed: April 2023     Priority: 1

Specific drugs prioritised to date:

• Vilobelimab (a human-mouse chimeric IgG4 kappa antibody that targets human C5a in plasma)

IL-6 receptor inhibitors

First reviewed: April 2023     Priority: 1

Specific drugs prioritised to date:

• Tocilizumab

TNF-alpha inhibitors

First reviewed: April 2023     Priority: 1

Specific drugs prioritised to date:

• Infliximab

Where there are multiple drugs in a class, the class is prioritised until the capacity exists for entry into the platform. At this point, a further exercise is undertaken to decide on the specific drug to be taken forward.

Under review

Artesunate

First reviewed: August 2023

Insufficient evidence at this time.

1. Need proof of concept data in human models

2. Need rational for dose regime to be used

3. Await data from ongoing SOLIDARITY trial

CRAC channel inhibitors

First reviewed: August 2023

Insufficient evidence at this time.

Specific drugs considered to date:

• Auxora (CM4620)

Furosemide

nebulised/inhaled

First reviewed: April 2023

Insufficient evidence at this time.

Galectin-3 inhibitors

First reviewed: April 2023

Insufficient evidence at this time.

Specific drugs considered to date:

• Belapectin (nebulised/inhaled)

Macrolides

First reviewed: April 2023

Insufficient evidence at this time.

p38 MAPK inhibitors

First reviewed: April 2023

Insufficient evidence at this time.

Specific drugs considered to date:

• Dilmapimod

PSCK9 inhibitors

First reviewed: August 2023

Insufficient evidence at this time.

Neutrophil elastase inhibitors

First reviewed: August 2023

Insufficient evidence at this time.

Specific drugs considered to date:

• Sivelestat

Sphingosine 1-phosphate receptor modulators

First reviewed: April 2023

Insufficient evidence at this time.

Specific drugs considered to date:

• Fingolimod

Tyrosine kinase inhibitors

Reviewed: 24-04-2023

Insufficient evidence at this time.

Specific drugs considered to date:

• Imatinib.

Not prioritised

Aspirin

Reviewed: 24-04-2023

Not prioritised on the basis of prevalence of use in the target population and poor recruitment in previous ARDS trials.

Citrulline

Reviewed: 24-04-2023

Not prioritised on the basis of insufficient evidence for efficacy and lack of biological plausibility.

Corticosteroids

Reviewed: 24-04-2023

Not prioritised on the basis of ongoing or proposed trials.

N-acetyl-cysteine

nebulised/inhaled

Reviewed: 24-04-2023

Not prioritised on the basis of insufficient evidence for efficacy and lack of biological plausibility.

Streptokinase

nebulised/inhaled

Reviewed: 24-04-2023

Not prioritised on the basis of insufficient evidence for efficacy and lack of biological plausibility.